Valneva SE (VALN) Non-Current Deferred Tax Liability (2019 - 2026)

Valneva SE (VALN) posted quarterly Non-Current Deferred Tax Liability of $5.0 million for Q1 2026, up 7.21% year-on-year from $4.7 million in Q1 2025, and little changed on a QoQ basis from $5.0 million in Q4 2025.

Valneva SE (VALN) Non-Current Deferred Tax Liability (2019 - 2026) Analysis & Trends

Valneva SE (VALN) has reported Non-Current Deferred Tax Liability for 8 consecutive years, with $5.0 million the latest figure, recorded in Q1 2026.

  • Quarterly Non-Current Deferred Tax Liability rose 7.21% year-over-year to $5.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.0 million (up 7.21% YoY) and the FY2025 annual result came in at $5.0 million, up 5.93% from the prior year.
  • Non-Current Deferred Tax Liability was little changed at $5.0 million in Q1 2026 per VALN's latest filing, from $5.0 million in the prior quarter.
  • Over the last five years, Non-Current Deferred Tax Liability for VALN reached as high as $14.8 million in Q4 2023 and fell as low as $789740.3 in Q4 2022.
  • A 5-year average of $4.0 million and a median of $4.3 million in 2024 frame the typical range for Non-Current Deferred Tax Liability.
  • Annual changes were most pronounced in 2023 — Non-Current Deferred Tax Liability soared 1768.44% — and 2024, when it tumbled 67.9%.
  • Year by year, Non-Current Deferred Tax Liability stood at $789740.3 in 2022, then surged by 1768.44% to $14.8 million in 2023, then tumbled by 67.9% to $4.7 million in 2024, then climbed by 5.93% to $5.0 million in 2025, then rose by 0.48% to $5.0 million in 2026.
  • According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods registered $5.0 million, $5.0 million, and $4.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Valneva SE 803.90 Mn 680.66 Mn 5.38 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 5.04 Mn
Mar 31, 2026 5.04 Mn
Dec 31, 2025 5.02 Mn
Dec 31, 2025 5.02 Mn
Sep 30, 2025 4.50 Mn
Sep 30, 2025 4.50 Mn
Jun 30, 2025 4.59 Mn
Jun 30, 2025 4.59 Mn
Mar 31, 2025 4.70 Mn
Mar 31, 2025 4.70 Mn
Dec 31, 2024 4.74 Mn
Dec 31, 2024 4.74 Mn
Sep 30, 2024 4.31 Mn
Sep 30, 2024 4.31 Mn
Jun 30, 2024 4.26 Mn
Jun 30, 2024 4.26 Mn
Mar 31, 2024 4.21 Mn
Mar 31, 2024 4.21 Mn
Dec 31, 2023 14.76 Mn
Dec 31, 2023 14.76 Mn